CELL LINES
Contributor Information
- Name Thorbald Van Hall
- Institute Leiden University and Leiden University Medical Center; Stichting Oncode Institute
Tool Details
- Tool name: RMA.Trh4 Db KO cells
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: RMA
- Organism: Mouse
- Tissue: Lymphatic Tissue
- Cancer type: Blood cancer
- Disease: Cancer
- Model: Knock-Out
- Description: This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Db gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore could present the Trh4 peptide. However, no T cell recognition can be observed due to the absence of the MHC class I H2-Db.This population acts as a clear control. CRISPR edited RMA cells.
- Research area: Cancer
- Production details: Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology
- Cellosaurus ID: CVCL_J385
- Additional notes: CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
- For Research Use Only
Target Details
- Target: Trh4 Db KO
Application Details
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license
Handling
- Format: Frozen
- Growth medium: Suspension cells in DMEM+8% FCS
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry ice
- Mycoplasma free: Yes
- Biosafety level: 1
Documentation
References
- • Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.
.svg)
Unit size: 
.svg)
.svg)
